Essential: The Pharmacy Compounding Podcast

In this episode, Andrew Kantor is joined by federal lobbyist David Pore and PCCA's Amy Shank to examine the proposed SAFE Act and its potential impact on compounding pharmacies. The discussion explores concerns that the...

<p>This episode we look at some of the latest compounding news, and then we’ve got a deep dive into state-level legislation with the Leading Ladies of Pharmacy Compounding Advocacy.<br> What bills are being introduced...

This episode we look at some of the latest compounding news, and then we’ve got a deep dive into state-level legislation with the Leading Ladies of Pharmacy Compounding Advocacy. What bills are being introduced? What do...

<p>This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with...

This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those? Our...

<p>This week we look at a somewhat confusing, possibly problematic FDA statement, as well as the anti-compounding bills popping up across the country. Our Deep Dive this week is a hot topic: AI in pharmacies — how it’s...

This week we look at a somewhat confusing, possibly problematic FDA statement, as well as the anti-compounding bills popping up across the country. Our Deep Dive this week is a hot topic: AI in pharmacies — how it’s...

<p>In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to pass laws restricting compounding, and second is a cryptic statement from...

In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to pass laws restricting compounding, and second is a cryptic statement from...

In this edition of Essential, we’ve got concerns about the FDA’s revolving door, some issues with a new California law that might affects the whole country, and a new accreditation that might save a lot of headache...

<p>In this edition of Essential, we’ve got concerns about the FDA’s revolving door, some issues with a new California law that might affects the whole country, and a new accreditation that might save a lot of headache...

<p>In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s...

In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s...

In this edition of Essential, we look at how we’re pushing back against the FDA’s upcoming ban on desiccated thyroid extract, why drugmakers’ latest tactics against compounding pharmacies are backfiring, and we give you...

<p>In this edition of Essential, we look at how we’re pushing back against the FDA’s upcoming ban on desiccated thyroid extract, why drugmakers’ latest tactics against compounding pharmacies are backfiring, and we give...